Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib and Bevacizumab in Advanced RCC
NCT00184015Phase 2Unknown
- Sponsor
- University of Southern California
- Start
- Aug 2005
- Primary completion
- Aug 2016
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bortezomib in renal cell carcinoma (RCC) (2 arms), sponsored by University of Southern California. Primary endpoint: Toxicity. Status: unknown.
02
Drugs
bortezomib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00184015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00184015.